(Q52716381)

English

Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.

scientific article published on 26 April 2018

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells. (English)

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

1 reference

based on heuristic

inferred from title

Serena Mazzucchelli

5

1 reference

Europe PubMed Central

PubMed publication ID

6 May 2018

http://europepmc.org/abstract/MED/29700387

author name string

Marta Truffi

1

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Miriam Colombo

2

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Luca Sorrentino

3

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Laura Pandolfi

4

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Francesco Pappalardo

6

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Chiara Pacini

7

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Raffaele Allevi

8

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Arianna Bonizzi

9

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Fabio Corsi

10

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Davide Prosperi

11

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

language of work or name

0 references

publication date

26 April 2018

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Scientific Reports

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

8

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

1

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

6563

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

copyright license

Creative Commons Attribution 4.0 International

26 April 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

describes a project that uses

1 reference

Europe PubMed Central

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5920071/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

https://scigraph.springernature.com/pub.10.1038/s41598-018-24968-x

0 references

Nanomedicine applications in the treatment of breast cancer: current state of the art.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Evolution of anti-HER2 therapies for cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Tumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Targeting natural killer cells in cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Trastuzumab beyond progression for HER2 positive metastatic breast cancer: progression-free survival on first-line therapy predicts overall survival impact

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Biotechnological approaches toward nanoparticle biofunctionalization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Controlled antibody/(bio-) conjugation of inorganic nanoparticles for targeted delivery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Trastuzumab: updated mechanisms of action and resistance in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Multiple presentation of Scfv800E6 on silica nanospheres enhances targeting efficiency toward HER-2 receptor in breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

HER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Association with membrane protrusions makes ErbB2 an internalization-resistant receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

14 June 2018

Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

13 August 2018

2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

13 August 2018

Assessing the in vivo targeting efficiency of multifunctional nanoconstructs bearing antibody-derived ligands.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5920071

13 August 2018

Dependence of nanoparticle-cell recognition efficiency on the surface orientation of scFv targeting ligands

1 reference

https://api.crossref.org/works/10.1038%2FS41598-018-24968-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/S41598-018-24968-X

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 June 2018

http://europepmc.org/abstract/PMC/5920071

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52716381&oldid=1895248116"